PLA2R1 mediates tumor suppression by activating JAK2

Cancer Research

Volumn 73, Issue 20, 2013, Pages 6334-6345

  Vindrieux, David ^a,b,c   Augert, Arnaud ^a,b,c,d   Girard, Christophe A ^e   Gitenay, Delphine ^a,b,c   Lallet Daher, Helene ^a,b,c   Wiel, Clotilde ^a,b,c   Le Calve, Benjamin ^a,b,c   Gras, Baptiste ^a,b,c   Ferrand, Mylene ^a,b,c   Verbeke, Stephanie ^f   De Launoit, Yvan ^d   Leroy, Xavier ^d,g   Puisieux, Alain ^a,b,c   Aubert, Sébastien ^d,g   Perrais, Michael ^g   Gelb, Michael ^h   Simonnet, Helene ^a,b,c   Lambeau, Gerard ^e   Bernard, David ^a,b,c  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b CENTRE LÉON BÉRARD   (France)

^c UNIVERSITÉ DE LYON   (France)

^d UNIV LILLE   (France)

^e INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^f UNIVERSITÉ DE BORDEAUX   (France)

^g JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE A2 RECEPTOR; PHOSPHOLIPASE A2 RECEPTOR 1; PROTEIN P16; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PLA2R1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SENESCENCE; SKIN CARCINOGENESIS; SKIN PAPILLOMA; TRANSCRIPTION INITIATION; TUMOR ESCAPE; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL AGING; CELL CULTURE TECHNIQUES; CELL GROWTH PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; HUMANS; IMMUNOHISTOCHEMISTRY; JANUS KINASE 2; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NIH 3T3 CELLS; RECEPTORS, PHOSPHOLIPASE A2; SKIN NEOPLASMS; TRANSFECTION;

EID: 84885961926     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0318     Document Type: Article

References (46)

1. Hahn WC, Counter CM, Lundberg A.S., Beijersbergen RL, Brooks MW, Weinberg RA Creation of human tumour cells with defined genetic elements. Nature 1999; 400:464-8.
2. Hanahan D, Weinberg RA The hallmarks of cancer. Cell 2000; 100: 57-70.
3. Bodnar AG, Ouellette M, Frolkis M., Holt SE, Chiu CP, Morin GB, et al Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279:349-52.
4. Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 1998; 8:279-82.
5. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010; 10:51-7.
6. Kuilman T, Michaloglou C, Mooi W.J., Peeper DS The essence of senescence. Genes Dev 2010; 24:2463-79.
7. Adams PD. Healing and hurting: molecular mechanisms, functions, and pathologies of cellular senescence. Mol Cell 2009; 36:2-14.
8. Ewald JA, Desotelle JA, Wilding G, Jarrard DF Therapy-induced senescence in cancer. J Natl Cancer Inst 2010; 102:1536-46.
9. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011; 11:503-11.
10. Augert A, Payre C, de Launoit Y, Gil J, Lambeau G., Bernard D. The Mtype receptor PLA2R regulates senescence through the p53 pathway. EMBO Rep 2009; 10:271-7.
11. Kim HJ, Kim KS, Kim S.H., Baek SH, Kim HY, Lee C, et al Induction of cellular senescence by secretory phospholipase A2 in human dermal fibroblasts through an ROS-mediated p53 pathway. J Gerontol A Biol Sci Med Sci 2009; 64:351-62.
12. Murakami M, Taketomi Y, Girard C., Yamamoto K, Lambeau G. Emerging roles of secreted phospholipase A2 enzymes: lessons from transgenic and knockout mice. Biochimie 2010; 92:561-82.
13. Llorca O. Extended and bent conformations of the mannose receptor family. Cell Mol Life Sci 2008; 65:1302-10.
14. Parganas E, Wang D, Stravopodis D., Topham DJ, Marine JC, Teglund S, et al Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93:385-95.
15. Beck LHjr, Bonegio RG, Lambeau G, Beck D.M., Powell DW, Cummins TD, et al M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361:11-21.
16. Sasaki A, Inagaki-Ohara K, Yoshida T., Yamanaka A, Sasaki M, Yasukawa H., et al The N-terminal truncated isoform of SOCS3 translated from an alternative initiation AUG codon under stress conditions is stable due to the lack of a major ubiquitination site, Lys-6. J Biol Chem 2003; 278:2432-6.
17. Young AR, Narita M, Ferreira M., Kirschner K, Sadaie M, Darot J.F., et al Autophagy mediates the mitotic senescence transition. Genes Dev 2009; 23:798-803.
18. Serrano M, Lin AW, McCurrach M.E., Beach D., Lowe SW Oncogenicras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88:593-602.
19. Hanasaki K, Yokota Y, Ishizaki J., Itoh T, Arita H. Resistance to endotoxic shock in phospholipase A2 receptor-deficient mice. J Biol Chem 1997; 272:32792-7.
20. Tron K, Samoylenko A, Musikowski G., Kobe F, Immenschuh S, Schaper F., et al Regulation of rat heme oxygenase-1 expression by interleukin-6 via the Jak/STAT pathway in hepatocytes. J Hepatol 2006; 45:72-80.
21. Debacq-Chainiaux F., Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SAbetagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 2009; 4:1798-806.
22. Abel EL, Angel JM, Kiguchi K, DiGiovanni J. Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat Protoc 2009; 4:1350-62.
23. Bizub D, Wood AW, Skalka AM Mutagenesis of the Ha-ras oncogene in mouse skin tumors induced by polycyclic aromatic hydrocarbons. Proc Natl Acad Sci USA 1986; 83:6048-52.
24. Rebouissou S, Amessou M, Couchy G., Poussin K, Imbeaud S, Pilati C., et al Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009; 457:200-4.
25. Constantinescu SN, Girardot M, Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem Sci 2008; 33:122-31.
26. Hexner EO. JAK2 V617F: implications for thrombosis in myeloproliferative diseases. Curr Opin Hematol 2007; 14:450-4.
27. Starr R, Willson TA, Viney E.M., Murray LJ, Rayner JR, Jenkins BJ, et al A family of cytokine-inducible inhibitors of signalling. Nature 1997; 387:917-21.
28. Okugawa S, Ota Y, Kitazawa T., Nakayama K, Yanagimoto S, Tsukada K., et al Janus kinase 2 is involved in lipopolysaccharide-induced activation of macrophages. Am J Physiol Cell Physiol 2003; 285: C399-C408.
29. Zhong J, Yang P, Muta K., Dong R, Marrero M, Gong F., et al Loss of Jak2 selectively suppresses DC-mediated innate immune response and protects mice from lethal dose of LPS-induced septic shock. PLoS One 2010; 5:e9593.
30. Stahl PD, Ezekowitz RA The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol 1998; 10:50-5.
31. Behrendt N, Jensen ON, Engelholm L.H., Mortz E., Mann M, Dano K. A urokinase receptor-associated protein with specific collagen binding properties. J Biol Chem 2000; 275:1993-2002.
32. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F., Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998; 334(Pt 2):297-314.
33. Taga T, Kishimoto T. Signaling mechanisms through cytokine receptors that share signal transducing receptor components. Curr Opin Immunol 1995; 7:17-23.
34. Ferrajoli A, Faderl S, Ravandi F., Estrov Z. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets 2006; 6:671-9.
35. Quintas-Cardama A., Kantarjian H, Cortes J., Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011; 10:127-40.
36. Borden EC, Sen GC, Uze G, Silverman R.H., Ransohoff RM, Foster GR, et al Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007; 6:975-90.
37. Moiseeva O, Mallette FA, Mukhopadhyay U.K., Moores A., Ferbeyre G. DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation. Mol Biol Cell 2006; 17: 1583-92.
38. Chawla-Sarkar M., Lindner DJ, Liu Y.F., Williams BR, Sen GC, Silverman RH, et al Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8:237-49.
39. Gresser I. Antitumor effects of interferon. Adv Cancer Res 1972; 16: 97-140.
40. Verma A, Kambhampati S, Parmar S., Platanias LC Jak family of kinases in cancer. Cancer Metastasis Rev 2003; 22:423-34.
41. Kuilman T, Michaloglou C, Vredeveld LCW, Douma S, van Doorn R, Desmet CJ, et al Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008; 133: 1019-31.
42. Kuilman T, Peeper DS Senescence-messaging secretome: Smsing cellular stress. Nat Rev Cancer 2009; 9:81-94.
43. Hubackova S, Novakova Z, Krejcikova K., Kosar M, Dobrovolna J, Duskova P., et al Regulation of the PML tumor suppressor in druginduced senescence of human normal and cancer cells by JAK/STATmediated signaling. Cell Cycle 2010; 9:3085-99.
44. Kojima H, Kunimoto H, Inoue T., Nakajima K. The STAT3-IGFBP5 axis is critical for IL-6/gp130-induced premature senescence in human fibroblasts. Cell Cycle 2012; 11:730-9.
45. Novakova Z, Hubackova S, Kosar M., Janderova-Rossmeislova L, Dobrovolna J, Vasicova P., et al Cytokine expression and signaling in drug-induced cellular senescence. Oncogene 2010; 29: 273-84.
46. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 2007; 21:43-8.